Skip to main content

Haemonetics Corp

corporate_fare Company Profile

Haemonetics Corp

HAE·NYSE·Industrial Applications And Services·CIK 0000313143

HAEMONETICS CORP is a global medical technology company focused on improving healthcare quality, effectiveness, and efficiency. The company provides innovative solutions for critical medical needs, including hospital technologies to advance care standards and enhance patient outcomes, end-to-end plasma collection technologies to optimize plasma center operations, and products enabling blood centers to collect in-demand blood components. HAEMONETICS CORP manages its business through three principal reporting segments: Plasma, Blood Center, and Hospital. The Plasma segment includes plasma collection devices and disposables, donor management software, and supporting software solutions sold to plasma customers. The Blood Center segment encompasses blood collection and processing devices and disposables for plasma, red cells, and platelets. The Hospital segment is comprised of Interventional Technologies, which includes Vascular Closure, Sensor-Guided Technologies, and Esophageal Protection product lines, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage, and Transfusion Management product lines. The availability of products can vary by country or region due to local regulatory approval requirements, and applicable laws may restrict product sale, distribution, or use to, by, or on the order of a licensed healthcare practitioner.

Haemonetics Corp (NYSE:HAE) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 13 items for HAE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 13 most recent items scored 7 or higher, the top rating is 8/10, with 8 rated 8 or above. Recent SEC coverage for HAE spans 8-K, DEF 14A, 10-K, 10-Q.

Recent high-impact activity:

  • Haemonetics Posts $358M in Q2 Revenue
  • Haemonetics Lifts FY27 Revenue Guidance to 8-11% on 10% Organic Q2 Growth
  • FDA Approves PerQseal Elite, Opening U.S. Large-Bore Closure Market
  • CSL to Complete Haemonetics Platform Rollout in US Plasma Centers by End 2027
  • Haemonetics Signs Non-Exclusive Supply Agreement with CSL Plasma for NexSys PCS Devices

Financial Snapshot

Fiscal year ended March 28, 2026
Revenue
$1.33B
Net Income
$97.31M
Diluted EPS
$2.05
Op. Cash Flow
$293.22M
Free Cash Flow
$260.44M
Gross Profit
$787.59M
Operating Income
$156.73M
Cash & Equivalents
$245.44M
Total Debt
$1.22B
Debt / Equity
1.54×
Net Margin
7.3%
Shares Outstanding
45.25M sh
Source: 10-K · filed 2026-05-20 · accession 0000313143-26-000050

Short Interest & Short Volume

6.27 days to cover

FINRA reported short interest of 3,599,250 shares in HAE as of the October 30, 2026 settlement, a 5.0% increase from the prior period — about 6.3 days to cover at its recent average daily volume. On November 20, 2026, 79.7% of HAE volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,599,250 shares as of October 30, 2026
Change vs prior period▲ 5.0%
Days to cover6.27 at avg daily volume of 574,460
Daily short volume (FINRA facilities)79.7% of 127,053 shares on November 20, 2026
5-day average short volume62.2%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with H →
$120.16
52-week range · as of 2026-11-05 $49.96 – $128.82
Market cap
$5.47B
Volume
383K (0.6× avg)
3-mo avg 658.7K
Live data · 2026-11-22 12:38 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed HAE - Latest Insights

HAE
Nov 05, 2026, 6:13 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $127.42
Real-time Price: $120.16 info
Change: -$7.26 (-6%) info
Market Cap: $5.472B info
HAE
Nov 05, 2026, 6:03 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $127.42
Real-time Price: $120.16 info
Change: -$7.26 (-6%) info
Market Cap: $5.472B info
HAE
Oct 19, 2026, 4:15 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $118.73
Real-time Price: $120.16 info
Change: +$1.43 (+1%) info
Market Cap: $5.472B info
HAE
Oct 08, 2026, 3:50 AM EDT
Source: Reuters
Importance Score:
8
Updated Oct 8, 6:16 AM ET — Haemonetics will provide an update on the supply agreement's fiscal 2027 financial impact during its second-quarter earnings call in Novemb…
Price at Filing: $101.71
Real-time Price: $120.16 info
Change: +$18.45 (+18%) info
Market Cap: $5.472B info
HAE
Aug 18, 2026, 6:03 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $96.06
Real-time Price: $120.16 info
Change: +$24.10 (+25%) info
Market Cap: $5.472B info
HAE
Aug 06, 2026, 6:07 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $83.50
Real-time Price: $120.16 info
Change: +$36.66 (+44%) info
Market Cap: $5.472B info
HAE
Jun 09, 2026, 4:17 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $78.71
Real-time Price: $120.16 info
Change: +$41.45 (+53%) info
Market Cap: $5.472B info
HAE
May 20, 2026, 6:31 AM EDT
Filing Type: 10-K
Importance Score:
8
Price at Filing: $56.85
Real-time Price: $120.16 info
Change: +$63.31 (+111%) info
Market Cap: $5.472B info
HAE
May 07, 2026, 6:10 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $54.35
Real-time Price: $120.16 info
Change: +$65.81 (+121%) info
Market Cap: $5.472B info
HAE
May 07, 2026, 6:02 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $54.35
Real-time Price: $120.16 info
Change: +$65.81 (+121%) info
Market Cap: $5.472B info
HAE
Mar 03, 2026, 6:09 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $63.32
Real-time Price: $120.16 info
Change: +$56.84 (+90%) info
Market Cap: $5.472B info
HAE
Feb 05, 2026, 6:05 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $70.00
Real-time Price: $120.16 info
Change: +$50.16 (+72%) info
Market Cap: $5.472B info
HAE
Jan 09, 2026, 6:17 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $84.04
Real-time Price: $120.16 info
Change: +$36.12 (+43%) info
Market Cap: $5.472B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets